Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease*

Pyroglutamate-modified amyloid-β (AβpE3) peptides are gaining considerable attention as potential key participants in the pathology of Alzheimer disease (AD) due to their abundance in AD brain, high aggregation propensity, stability, and cellular toxicity. Transgenic mice that produce high levels of AβpE3–42 show severe neuron loss. Recent in vitro and in vivo experiments have proven that the enzyme glutaminyl cyclase catalyzes the formation of AβpE3. In this minireview, we summarize the current knowledge on AβpE3, discussing its discovery, biochemical properties, molecular events determining formation, prevalence in the brains of AD patients, Alzheimer mouse models, and potential as a target for therapy and as a diagnostic marker.

• Publication year

  2011

• Venue

  Journal of Biological Chemistry

• Publication date

  2011-09-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1074/jbc.R111.288308PMID 21965666PMCID PMC3234707
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease.

  2012cited by this paper
• Extracellular phosphorylation of the amyloid β‐peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease

  2011cited by this paper
• Glutaminyl Cyclase Knock-out Mice Exhibit Slight Hypothyroidism but No Hypogonadism

  2011cited by this paper
• Potent amyloidogenicity and pathogenicity of Aβ43

  2011cited by this paper
• Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease.

  2011cited by this paper
• Alzheimer's Aβ Peptides with Disease-Associated N-Terminal Modifications: Influence of Isomerisation, Truncation and Mutation on Cu2+ Coordination

  2010cited by this paper
• Overexpression of Glutaminyl Cyclase, the Enzyme Responsible for Pyroglutamate Aβ Formation, Induces Behavioral Deficits, and Glutaminyl Cyclase Knock-out Rescues the Behavioral Phenotype in 5XFAD Mice*

  2010cited by this paper
• Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis.

  2010cited by this paper
• Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease

  2010cited by this paper
• A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo

  2010cited by this paper
• Developmental expression and subcellular localization of glutaminyl cyclase in mouse brain

  2009cited by this paper
• Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases

  2009cited by this paper
• Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.

  2009cited by this paper
• Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease

  2009cited by this paper
• Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model

  2009cited by this paper
• Aminopeptidase A contributes to the N‐terminal truncation of amyloid β‐peptide

  2009cited by this paper
• APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy

  2009cited by this paper
• Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta.

  2008cited by this paper
• Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease.

  2008cited by this paper
• N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis

  2008cited by this paper
• Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice

  2008cited by this paper
• Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology

  2008cited by this paper
• Inhibition of glutaminyl cyclase prevents pGlu‐Aβ formation after intracortical/hippocampal microinjection in vivo/in situ

  2008cited by this paper
• Isolation of an isoenzyme of human glutaminyl cyclase: retention in the Golgi complex suggests involvement in the protein maturation machinery.

  2008cited by this paper
• Age-dependent axonal degeneration in an Alzheimer mouse model.

  2007cited by this paper
• Aβ Oligomers – a decade of discovery

  2007cited by this paper
• Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography

  2007cited by this paper
• Monoclonal antibodies that target pathological assemblies of Aβ

  2007cited by this paper
• Quantification of Alzheimer pathology in ageing and dementia: age‐related accumulation of amyloid‐β(42) peptide in vascular dementia

  2006cited by this paper
• Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells.

  2006cited by this paper
• On the seeding and oligomerization of pGlu-amyloid peptides (in vitro).

  2006cited by this paper
• A specific amyloid-β protein assembly in the brain impairs memory

  2006cited by this paper
• Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation

  2006cited by this paper
• A specific amyloid-beta protein assembly in the brain impairs memory.

  2006cited by this paper
• Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

  2005cited by this paper
• Biological significance of isoaspartate and its repair system.

  2005cited by this paper
• Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer's disease.

  2005cited by this paper
• Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β

  2005cited by this paper
• Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo

  2005cited by this paper
• beta-amyloid is different in normal aging and in Alzheimer disease.

  2005cited by this paper
• Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.

  2005cited by this paper
• β-Amyloid Is Different in Normal Aging and in Alzheimer Disease*

  2005cited by this paper
• Role of water‐soluble amyloid‐β in the pathogenesis of Alzheimer's disease

  2005cited by this paper
• Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model.

  2004cited by this paper
• A modified β‐amyloid hypothesis: intraneuronal accumulation of the β‐amyloid peptide – the first step of a fatal cascade

  2004cited by this paper
• Oligomerization of Alzheimer's β-Amyloid within Processes and Synapses of Cultured Neurons and Brain

  2004cited by this paper
• Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions

  2004cited by this paper
• Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence.

  2003cited by this paper
• Identification of Human Glutaminyl Cyclase as a Metalloenzyme

  2003cited by this paper
• β-Secretase Processing in the Trans-Golgi Network Preferentially Generates Truncated Amyloid Species That Accumulate in Alzheimer's Disease Brain*

  2002cited by this paper
• Antibodies to β-Amyloid Decrease the Blood-to-Brain Transfer of β-Amyloid Peptide1

  2002cited by this paper
• Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain.

  2002cited by this paper
• Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus

  2002cited by this paper
• Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

  2002cited by this paper
• Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.

  2001cited by this paper
• Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

  2001cited by this paper
• Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

  2001cited by this paper
• Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

  2001cited by this paper
• Phosphorylation of amyloid-beta at the serine 26 residue by human cdc2 kinase.

  2001cited by this paper
• Phosphorylation of amyloid-β at the serine 26 residue by human cdc2 kinase

  2001cited by this paper
• Comparative Analysis of Amyloid-β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains*

  2001cited by this paper
• Identification of Amino-Terminally and Phosphotyrosine-Modified Carboxy-Terminal Fragments of the Amyloid Precursor Protein in Alzheimer's Disease and Down's Syndrome Brain

  2001cited by this paper
• Presenilin-1 mutations in Alzheimer's disease

  2000cited by this paper
• Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain.

  2000cited by this paper
• Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

  2000cited by this paper
• The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain.

  2000cited by this paper
• SDS-stable complex formation between native apolipoprotein E3 and beta-amyloid peptides.

  2000cited by this paper
• Amyloid β protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain

  2000cited by this paper
• On-line high-performance liquid chromatography/mass spectrometric investigation of amyloid-beta peptide variants found in Alzheimer's disease.

  1999cited by this paper
• Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

  1999cited by this paper
• Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

  1999cited by this paper
• The Aβ 3-Pyroglutamyl and 11-Pyroglutamyl Peptides Found in Senile Plaque Have Greater β-Sheet Forming and Aggregation Propensities in Vitro than Full-Length Aβ†

  1999cited by this paper
• The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta.

  1999cited by this paper
• Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease

  1999cited by this paper
• Toxicity of Pyroglutaminated Amyloid β‐Peptides 3(pE)‐40 and ‐42 Is Similar to That of Aβ1‐40 and ‐42

  1999cited by this paper
• Toxicity of pyroglutaminated amyloid beta-peptides 3(pE)-40 and -42 is similar to that of A beta1-40 and -42.

  1999cited by this paper
• Quantification of Modified Amyloid β Peptides in Alzheimer Disease and Down Syndrome Brains

  1998cited by this paper
• Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease.

  1998cited by this paper
• Heterogeneity of water‐soluble amyloid β‐peptide in Alzheimer's disease and Down's syndrome brains

  1997cited by this paper
• Disaggregation of Alzheimer β-amyloid by site-directed mAb

  1997cited by this paper
• Amyloid beta-protein (Abeta) 1-40 but not Abeta1-42 contributes to the experimental formation of Alzheimer disease amyloid fibrils in rat brain.

  1997cited by this paper
• Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

  1997cited by this paper
• Amyloid β-Protein (Aβ) 1–40 But Not Aβ1–42 Contributes to the Experimental Formation of Alzheimer Disease Amyloid Fibrils in Rat Brain

  1997cited by this paper
• Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain.

  1996cited by this paper
• Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

  1996cited by this paper
• Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains.

  1996cited by this paper
• Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (*)

  1996cited by this paper
• High‐Resolution Separation of Amyloid β‐Peptides: Structural Variants Present in Alzheimer's Disease Amyloid

  1996cited by this paper
• Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.

  1995cited by this paper
• Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro.

  1995cited by this paper
• Amino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro(*)

  1995cited by this paper
• Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid.

  1994cited by this paper
• Racemization: its biological significance on neuropathogenesis of Alzheimer's disease.

  1994cited by this paper
• Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging.

  1994cited by this paper
• Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues.

  1994cited by this paper
• Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)

  1994cited by this paper
• Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

  1994cited by this paper
• Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease.

  1993cited by this paper
• Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease.

  1993cited by this paper
• beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.

  1993cited by this paper

• 17O quadrupolar chemical exchange saturation transfer (Q-CEST) NMR for investigations of molecular dynamics in solids.

  2026cites this paper
• Relationship between efficacy and preferential targeting of soluble Aβ aggregates

  2025cites this paper
• A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies

  2025cites this paper
• Amyloid Beta in Alzheimer's Disease: Mechanisms, Biomarker Potential, and Therapeutic Targets

  2025cites this paper
• Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation

  2025cites this paper
• Discovery of Proteoforms Associated With Alzheimer's Disease Through Quantitative Top-Down Proteomics

  2025cites this paper
• Development of triazole-based positron emission tomography ligands targeting glutaminyl cyclases (QCs) in the brain.

  2025cites this paper
• NeuproGemp, a polyphenol-rich botanical formula, ameliorates Alzheimer’s-like pathology in APP/PS1 mice via inhibition of human glutaminyl cyclase

  2025cites this paper
• Oxidative stress induced protein aggregation via GGCT produced pyroglutamic acid in drug resistant glioblastoma

  2025cites this paper
• Advances of therapeutic strategies for Alzheimer’s disease

  2025cites this paper
• Alzheimer's Disease and Frontotemporal Dementia: A Review of Pathophysiology and Therapeutic Approaches

  2025cites this paper
• Comprehensive medicinal chemistry survey highlights a portfolio of lead molecules for Alzheimer’s disease therapy

  2025cites this paper
• Associations of Plasma Glutamatergic Metabolites with Alpha Desynchronization during Cognitive Interference and Working Memory Tasks in Asymptomatic Alzheimer’s Disease

  2024cites this paper
• Conformation of Pyroglutamated Amyloid β (3–40) and (11–40) Fibrils – Extended or Hairpin?

  2024cites this paper
• Amyloid-α Peptide Formed through Alternative Processing of the Amyloid Precursor Protein Attenuates Alzheimer's Amyloid-β Toxicity via Cross-Chaperoning.

  2024cites this paper
• A Screen of Plant-Based Natural Products Revealed That Quercetin Prevents Pyroglutamylated Amyloid-β (Aβ3(pE)-42) Uptake in Astrocytes As Well As Resulting Astrogliosis and Synaptic Dysfunction

  2024cites this paper
• Pyroglutamylation modulates electronic properties and the conformational ensemble of the amyloid β‐peptide

  2024cites this paper
• Targeting the hydrophobic region of pyroglutamate‐modified amyloid‐β by tyrocidine A prevents its nucleation–aggregation process and its “catalytic effect” on the Aβs aggregation

  2024cites this paper
• Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease

  2024cites this paper
• Amyloid-β-targeting immunotherapies for Alzheimer's disease.

  2024cites this paper
• Serine phosphorylation mimics of Aβ form distinct, non-cross-seeding fibril morphs

  2024cites this paper
• Metabolic resistance of Aβ3pE-42, a target epitope of the anti-Alzheimer therapeutic antibody, donanemab

  2024cites this paper
• The Effects of Sevoflurane and Aβ Interaction on CA1 Dendritic Spine Dynamics and MEGF10-Related Astrocytic Synapse Engulfment

  2024cites this paper
• Anti-amyloid Antibody Therapies for Alzheimer’s Disease

  2024cites this paper
• Structure-activity relationship of dual inhibitors containing maleimide and imidazole motifs against glutaminyl cyclase and glycogen synthase kinase-3β.

  2024cites this paper
• Pyroglutamination-Induced Changes in the Physicochemical Features of a CXCR4 Chemokine Peptide: Kinetic and Structural Analysis.

  2023cites this paper
• Monoclonal Antibody Therapy in Alzheimer’s Disease

  2023cites this paper
• Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update

  2023cites this paper
• Design, synthesis and anti-AD effects of dual inhibitor targeting glutaminyl cyclase/GSK-3β.

  2023cites this paper
• Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease

  2023cites this paper
• Solid-phase synthesis and pathological evaluation of pyroglutamate amyloid-β3-42 peptide

  2023cites this paper
• Boronic Acid Resin for Selective Immobilization of Canonically Encoded Proteins.

  2023cites this paper
• Current Anti-Amyloid-β Therapy for Alzheimer’s Disease Treatment: From Clinical Research to Nanomedicine

  2023cites this paper
• Pyroglutamate-modified amyloid β(3-42) monomer has more β-sheet content than the amyloid β(1-42) monomer.

  2023cites this paper
• Polymorphic amyloid nanostructures of hormone peptides involved in glucose homeostasis display reversible amyloid formation

  2023cites this paper
• Astrocytic uptake of posttranslationally modified amyloid-β leads to endolysosomal system disruption and induction of pro-inflammatory signaling

  2023influential citation
• Alzheimer’s Disease and Its Possible Evolutionary Origin: Hypothesis

  2023influential citation
• Long-term supplementation with anthocyanin-rich or -poor Rubus idaeus berries does not influence microvascular architecture nor cognitive outcome in the APP/PS-1 mouse model of Alzheimer’s disease

  2022cites this paper
• Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents.

  2022cites this paper
• Amyloid-beta targeted therapeutic approaches for Alzheimer's disease: long road ahead.

  2022cites this paper
• An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer’s disease: pyroglutamate amyloid beta

  2022cites this paper
• The Small Molecule GAL-201 Efficiently Detoxifies Soluble Amyloid β Oligomers: New Approach towards Oral Disease-Modifying Treatment of Alzheimer’s Disease

  2022cites this paper
• Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases.

  2022cites this paper
• Intrathecal Contrast-Enhanced Magnetic Resonance Imaging of Cerebrospinal Fluid Dynamics and Glymphatic Enhancement in Idiopathic Normal Pressure Hydrocephalus

  2022cites this paper
• Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders

  2022cites this paper
• Cathepsin B - A Neuronal Death Mediator in Alzheimer's Disease Leads to Neurodegeneration.

  2022cites this paper
• Putative Structures of Membrane-Embedded Amyloid β Oligomers.

  2022cites this paper
• Refining the amyloid β peptide and oligomer fingerprint ambiguities in Alzheimer’s disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma

  2021cites this paper
• Postmortem Neocortical 3H-PiB Binding and Levels of Unmodified and Pyroglutamate Aβ in Down Syndrome and Sporadic Alzheimer’s Disease

  2021cites this paper
• N-Truncated Aβ Starting at Position Four—Biochemical Features, Preclinical Models, and Potential as Drug Target in Alzheimer’s Disease

  2021cites this paper
• Mutual structural effects of unmodified and pyroglutamylated amyloid β peptides during aggregation

  2021cites this paper
• Insights Into the Mechanism of Tyrosine Nitration in Preventing β-Amyloid Aggregation in Alzheimer’s Disease

  2021cites this paper
• Clinical application of intrathecal gadobutrol for assessment of cerebrospinal fluid tracer clearance to blood

  2021cites this paper
• Citrullination of Amyloid-β Peptides in Alzheimer's Disease.

  2021cites this paper
• Biological and methodological complexities of beta‐amyloid peptide: Implications for Alzheimer’s disease research

  2021cites this paper
• Novel Phosphorylation-State Specific Antibodies Reveal Differential Deposition of Ser26 Phosphorylated Aβ Species in a Mouse Model of Alzheimer’s Disease

  2021cites this paper
• The Dynamics of β-Amyloid Proteoforms Accumulation in the Brain of a 5xFAD Mouse Model of Alzheimer’s Disease

  2021cites this paper
• Discovery of a novel pseudo β-hairpin structure of N-truncated amyloid-β for use as a vaccine against Alzheimer’s disease

  2021cites this paper
• Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design.

  2021cites this paper
• Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers

  2021cites this paper
• Boronic Acid Reagents for Transition‐Metal‐Mediated Cross‐Coupling with Proteins and Peptides

  2021cites this paper
• Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors.

  2021cites this paper
• Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease

  2021cites this paper
• Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

  2021cites this paper
• Solid-state NMR reveals a comprehensive view of the dynamics of the flexible, disordered N-terminal domain of amyloid- (cid:2) fibrils

  2020cites this paper
• Structural characteristics of oligomers formed by pyroglutamate-modified amyloid β peptides studied by solid-state NMR.

  2020cites this paper
• In vivo Imaging With 18F-FDG- and 18F-Florbetaben-PET/MRI Detects Pathological Changes in the Brain of the Commonly Used 5XFAD Mouse Model of Alzheimer's Disease

  2020cites this paper
• The N-terminal modified Aβ variants enable modulations to the structures and cytotoxicity levels of wild-type Aβ fibrils through cross-seeding.

  2020cites this paper
• Magnetic resonance imaging biomarkers of cerebrospinal fluid tracer dynamics in idiopathic normal pressure hydrocephalus

  2020cites this paper
• Acetylation of Aβ42 at lysine 16 disrupts amyloid formation.

  2020cites this paper
• Effects of N-Terminal Residues on the Assembly of Constrained β-Hairpin Peptides Derived from Aβ.

  2020cites this paper
• Functionalized Mesoporous Silicas Direct Structural Polymorphism of Amyloid-β Fibrils

  2020cites this paper
• Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation

  2020cites this paper
• Quantitative Mass Spectrometric Assay of Whole and CNBr-Cleaved Amyloid-β Peptides in Human Brain

  2020cites this paper
• Novel monoclonal antibody 3B8 specifically recognizes pyroglutamate-modified amyloid β 3-42 peptide in brain of AD patients and 3xTg-AD transgenic mice.

  2020cites this paper
• High-yield Production of Amyloid-β Peptide Enabled by a Customized Spider Silk Domain

  2020cites this paper
• A molecular mechanism by which amyloid-β induces inactivation of CREB in Alzheimer’s Disease

  2020cites this paper
• Energy-dependent transport at dural lymphatic vessels is necessary for Aβ brain clearance in Alzheimer’s disease

  2019cites this paper
• Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2.

  2019cites this paper
• Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease

  2019cites this paper
• Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer's Agents by Structure-Based Design.

  2019cites this paper
• Transplantation of bone marrow derived macrophages reduces markers of neuropathology in an APP/PS1 mouse model

  2019cites this paper
• Solid-state NMR reveals a comprehensive view of the dynamics of the flexible, disordered N-terminal domain of amyloid-β fibrils

  2019cites this paper
• Glutaminyl cyclase inhibitor contributes to the regulation of HSP70, HSP90, actin, and ribosome on gene and protein levels in vitro

  2019cites this paper
• Glutaminyl cyclase inhibitor exhibits anti-inflammatory effects in both AD and LPS-induced inflammatory model mice.

  2019cites this paper
• A vaccine against Alzheimer`s disease: anything left but faith?

  2019cites this paper
• Deuteron Solid-State NMR Relaxation Measurements Reveal Two Distinct Conformational Exchange Processes in the Disordered N-Terminal Domain of Amyloid-β Fibrils.

  2019cites this paper
• 18F-FDG-PET Detects Drastic Changes in Brain Metabolism in the Tg4–42 Model of Alzheimer’s Disease

  2019cites this paper
• F-FDG-PET Detects Drastic Changes in Brain Metabolism in the Tg 4 – 42 Model of Alzheimer ’ s Disease

  2019cites this paper
• Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade.

  2018cites this paper
• Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice

  2018cites this paper
• A Naturally Encoded Dipeptide Handle for Bioorthogonal Chan-Lam Coupling.

  2018cites this paper
• Positive Feedback Loops in Alzheimer’s Disease: The Alzheimer’s Feedback Hypothesis

  2018cites this paper
• Cu(II) binding to various forms of amyloid-β peptides. Are they friends or foes?

  2018cites this paper
• Identifying hQC Inhibitors of Alzheimer’s Disease by Effective Customized Pharmacophore-Based Virtual Screening, Molecular Dynamic Simulation, and Binding Free Energy Analysis

  2018cites this paper
• The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid‐beta (A&bgr;) species on long‐term potentiation (LTP)

  2018cites this paper
• Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease

  2018cites this paper
• Modified amyloid variants in pathological subgroups of β‐amyloidosis

  2018cites this paper
• Cone Snail Glutaminyl Cyclase Sequences from Transcriptomic Analysis and Mass Spectrometric Characterization of Two Pyroglutamyl Conotoxins.

  2018cites this paper
• Trace amounts of pyroglutaminated Aβ-(3-42) enhance aggregation of Aβ-(1-42) on neuronal membranes at physiological concentrations: FCS analysis of cell surface.

  2018cites this paper